Neovir injection 12.5% 5 vials

Neovir (Natrii oxodihydroacridinylacetas, Oxodihydroacridinylacetate sodium) - iImmunostimulatory preparation. It has antiviral activity against DNA and RNA-virus genome. It has expressed protivohlamidiynoe action. Drug activity is related to its ability to induce high titers in the body endogenous interferon, especially alpha interferon.

V / m Neovir administration at a dose of 250 mg on identified serum concentrations of interferon is equivalent to the introduction of 6-9 mln.ME recombinant interferon alpha.

Neovir activates bone marrow stem cells, T-lymphocytes and macrophages. Exhibits immunomodulatory activity, normalizes the balance between subpopulations of T-helper and T-suppressor cells. In some diseases Neovir able to reduce production in the body of tumor necrosis factor (HIV, herpes) and activate natural killer cells (when the tumor diseases). Significantly increases the activity of polymorphonuclear leukocytes.

When HIV Neovir exerts immunomodulatory effects: increasing activity of blood serum absorption, increases the ability of leukocytes to synthesize interferon alpha, stimulates the formation of reactive oxygen phagocytes.

Peak interferon activity in blood and tissues is observed several hours after administration Neovir and maintained for 16-20 h.

Testimony:

• As an immunostimulatory agent in combination therapy:
• prevention and treatment of influenza and other acute respiratory diseases (including on the background of immunodeficiency states);
• infections caused by Herpes simplex virus type 1 and type 2 virus and Varicella zoster (including in individuals with compromised immune systems);
• CMV infection in patients with immune deficiency;
• Radiation immunodeficiency;
• treatment of HIV infection;
• encephalitis and encephalomyelitis virus etiology;
• acute and chronic hepatitis B and C;
• urethritis, epididymitis, prostatitis, cervicitis, and salpingitis chlamydial infection;
• LGV;
• oncological diseases;
• multiple sclerosis;
• candidiasis of skin and mucous membranes.

Contraindications:

• renal failure severe (CC less than 30 ml / min);
• autoimmune diseases;
• pregnancy;
• lactation (breastfeeding);
• childhood;
• hypersensitivity to the drug.

To apply caution in elderly patients.

Side effects:

Common reaction: low-grade fever, and allergic reactions.

Local reactions: Local quickly passing soreness at the site of administration.

Drug interactions:

During the clinical trials and the use of the drug in clinical practice have been no cases of incompatibility or potentiation of drug interaction with other drugs.

Information on the physical and chemical incompatibility Neovir with other drugs available

Suggested Use:

Injection solution is introduced into / m, a single dose of 250 mg (1 amp.) Or 4.6 mg / kg body weight. If necessary Neovir single dose may be increased to 500 mg.

The course of treatment, unless otherwise stated, consists of a 5-7 / m injection in single dose every 48 h. The course dose depends on the clinical picture. Duration of the course - 8-12 days. With long-term prophylactic use and the interval between infusions Neovir is 3-7 days.

When HIV injection is used in a combination therapy. The course of treatment consists of 10 v / m injections of 250 mg every 48 hours between injections. make a break after 2 months of a course of therapy. The number of repeated courses is not limited.

Packaging:

• Comes in original packaging. Item is brand new and unopened.

Storage:

• Keep away from direct sunlight.
• Keep locked and away from children.
• Store in dry place at room temperature.
• Do not exceed storage temperature higher than 25 C

Important notice- the outer box design may vary before prior notice!